QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...
The test was developed by researchers at the US-based not-for-profit Brain Chemistry Labs, who analysed 788 blood samples – roughly half from patients with the disease and half from people without it.